SCHEMBL22337189

SCHEMBL22337189

Brc1cccc(SCCC2CCCCCCC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CTSK P43235 1/20 0.41
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.38
MAOB P27338 2/20 0.37
KDM1A O60341 1/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CCNA1 P78396 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
RORC P51449 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21609713 1.00 MAOA (0.43) MAOAMEN1KMT2ACTSKALDH1A1
SCHEMBL1710821 0.91 MAOA (0.41) MAOAMEN1KMT2ACTSKALDH1A1
SCHEMBL1710383 0.84 CTSK (0.48) MAOAMEN1KMT2ACTSKALDH1A1
SCHEMBL13400234 0.84 CTSK (0.48) MAOAMEN1KMT2ACTSKALDH1A1
SCHEMBL1710511 0.82 CTSK (0.49) MAOAMEN1KMT2ACTSKALDH1A1
SCHEMBL1710391 0.81 MAOA (0.43) MAOAMEN1KMT2ACTSKALDH1A1
SCHEMBL22337074 0.80 HDAC3 (0.41) MAOAMEN1KMT2ACTSKALDH1A1
SCHEMBL21609724 0.80 HDAC3 (0.41) MAOAMEN1KMT2ACTSKALDH1A1
SCHEMBL30753727 0.77 MAOA (0.58) MAOAMEN1KMT2AALDH1A1MAOB
SCHEMBL6489460 0.77 APEX1 (0.54) MEN1KMT2AALDH1A1DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200255457-A1 PROCESS FOR THE REMOVAL AND RETURN OF A CATALYST TO A LIQUID PHASE MEDIUM PHOSPHONICS LTD (GB) 2020-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255457-A1 PROCESS FOR THE REMOVAL AND RETURN OF A CATALYST TO A LIQUID PHASE MEDIUM MSR1, NOC2L, GFRA2 MAOA 1486/4885MEN1 3932/4885KMT2A 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.